Page last updated: 2024-12-05

3-methylpyridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-Methylpyridine, also known as beta-picoline, is a heterocyclic aromatic compound. It is a colorless liquid with a pungent odor. It is a valuable building block in the synthesis of various pharmaceuticals, agrochemicals, and industrial chemicals. It finds applications in the production of herbicides, insecticides, and dyes. Its synthesis is typically achieved by the reaction of pyridine with methyl bromide in the presence of a base. 3-methylpyridine exhibits biological activity, including antifungal and antibacterial properties, and is under investigation for its potential therapeutic applications. Its importance stems from its versatility as a precursor in organic synthesis, and its potential as a starting material for the development of new drugs and other valuable compounds.'

3-methylpyridine : A methylpyridine that is pyridine substituted by a methyl group at position 3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7970
CHEMBL ID15722
CHEBI ID39922
MeSH IDM0151769

Synonyms (71)

Synonym
.beta.-picoline
3-picoline
108-99-6
3-methylpyridine
m-picoline
pyridine, 3-methyl-
.beta.-methylpyridine
nsc-18251
nsc18251
inchi=1/c6h7n/c1-6-3-2-4-7-5-6/h2-5h,1h
NCGC00091447-01
beta-picoline
MLS001065607
smr000568465
3-methyl pyridine
ai3-24110
beta-methylpyridine
hsdb 4254
nsc 18251
ccris 1722
einecs 203-636-9
3-methylpyridine, 99%
m-methylpyridine
3-mepy
CHEBI:39922 ,
DB01996
3-methylpyridine, >=99.5%
NCIOPEN2_004641
CHEMBL15722
3-methylpyridine-d7
P0416
AKOS000119862
NCGC00091447-02
m-picoline [un2313] [flammable liquid]
unii-b083j4kf7f
ec 203-636-9
b083j4kf7f ,
HMS3039L05
NCGC00256559-01
tox21_303001
cas-108-99-6
dtxcid201897
dtxsid9021897 ,
tox21_201966
NCGC00259515-01
STL282747
FT-0616178
AM81278
methylpyridine, 3-
.beta.-picoline [iarc]
.beta.-picoline [mi]
3-methylpyridine [hsdb]
3-methypyridine
3-methyl pyridin
meta-methylpyridine
5-methylpyridine
W-108710
F0001-0187
mfcd00006402
5hs ,
3-picoline, analytical standard
b-picoline
BCP22897
Q2697560
BCP26368
EN300-19742
PD008234
beta-picoline (iarc)
picoline (flammable liquid label)
pyridine, 3-methyl
Z104475010

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" In the pyridine series, compound 7a was found to be a highly potent and selective EP4 antagonist, with suitable rat and dog pharmacokinetic profiles."( Discovery of potent aryl-substituted 3-[(3-methylpyridine-2-carbonyl) amino]-2,4-dimethyl-benzoic acid EP4 antagonists with improved pharmacokinetic profile.
Blanco, MJ; Chambers, M; Chandrasekhar, S; Fisher, MJ; Harvey, A; Lin, C; Mudra, D; Oskins, J; Vetman, T; Wang, XS; Warshawsky, AM; Yu, XP, 2016
)
0.7

Dosage Studied

ExcerptRelevanceReference
" Pyridines, which were the most abundant class of compounds identified, were purchased, assayed for purity, and tested in dose-response studies on hamster oviducts."( Pyridines in cigarette smoke inhibit hamster oviductal functioning in picomolar doses.
Arey, J; Iv, M; Riveles, K; Talbot, P,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
methylpyridine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency5.44830.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency24.70820.000714.592883.7951AID1259369
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency34.66540.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency68.58960.003041.611522,387.1992AID1159553
estrogen nuclear receptor alphaHomo sapiens (human)Potency21.87240.000229.305416,493.5996AID743069
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency0.70790.707936.904389.1251AID504333
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency50.11870.001019.414170.9645AID588537
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.00070.010039.53711,122.0200AID588545
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency1.45810.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1145387Partition coefficient, log P of the compound by HPLC analysis1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Direct measurement of octanol-water partition coefficients by high-pressure liquid chromatography.
AID213129Inhibition of Thromboxane synthetase at 100 uM1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives.
AID1145386Partition coefficient, log P of the compound by shake-flask technique1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Direct measurement of octanol-water partition coefficients by high-pressure liquid chromatography.
AID30379Compound was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 11985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30378Maximum percent of inhibition of binding was determined1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (36.00)18.7374
1990's1 (4.00)18.2507
2000's6 (24.00)29.6817
2010's8 (32.00)24.3611
2020's1 (4.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.03

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.03 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index60.33 (26.88)
Search Engine Supply Index2.03 (0.95)

This Compound (42.03)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]